546 J.M. Walker and A.G. Hohmann
Dray A (1995) Inflammatory mediators of pain. Br J Anaesth 75:125–131
Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V (2000) Activation of spinal cannabinoid
1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases
[35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and
inflamed rats. Eur J Neurosci 12:2079–2086
Egertová M, Giang DK, Cravatt BF, Elphick MR (1998) A new perspective on cannabi-
noid signalling: complementary localization of fatty acid amide hydrolase and the CB1
receptor in rat brain. Proc R Soc Lond B Biol Sci 265:2081–2085
Egertová M, Cravatt BF, Elphick MR (2003) Comparative analysis of fatty acid amide hy-
drolase and CB(1) cannabinoid receptor expression in the mouse brain: evidence of
a widespread role for fatty acid amide of endocannabinoid signaling. Neuroscience
119:481–496
Ellington HC, Cotter MA, Cameron NE, Ross RA (2002) The effect of cannabinoids on
capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw
skin of diabetic and non-diabetic rats. Neuropharmacology 42:966–975
Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR (2000)
Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 15:510–521
Farquhar-Smith WP, Jaggar SI, Rice AS (2002) Attenuation of nerve growth factor-induced
visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97:11–21
Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA (1993) Anandamide,
an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid
receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci U S
A 90:7656–7660
FezzaF,BisognoT,MinassiA,AppendinoG,MechoulamR,DiMarzoV(2002)Noladinether,
a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for
its quantification in rat tissues. FEBS Lett 513:294–298
Fields HL, Heinricher MM, Mason P (1991) Neurotransmitters in nociceptive modulatory
circuits. Annu Rev Neurosci 14:219–245
Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I (2001) The role of central
and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids
in a model of neuropathic pain. Pain 92:91–100
FrideE(1995)Anandamides:toleranceandcross-tolerancetodelta9-tetrahydrocannabinol.
Brain Res 697:83–90
Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist,
anandamide, a brain constituent. Eur J Pharmacol 231:313–314
Galeazza MT, Garry MG, Yost HJ, Strait KA, Hargreaves KM, Seybold VS (1995) Plasticity in
the synthesis and storage of substance P and calcitonin gene-related peptide in primary
afferent neurons during peripheral inflammation. Neuroscience 66:443–458
Gilbert PE (1981) A comparison of THC, nantradol, nabilone, and morphine in the chronic
spinal dog. J Clin Pharmacol 21:311S–319S
Gong LW, Ding YQ, Wang D, Zheng HX, Qin BZ, Li JS, Kaneko T, Mizuno N (1997) GABAergic
synapses on mu-opioid receptor-expressing neurons in the superficial dorsal horn: an
electron microscope study in the cat spinal cord. Neurosci Lett 227:33–36
Grant G (1995) Primary afferent projections to the spinal cord. In: Paxinos G (ed) The Rat
Nervous System, 2nd edn. Academic Press, San Diego, pp 61–65
GriffinG,FernandoSR,RossRA,McKayNG,AshfordML,ShireD,HuffmanJW,YuS,Lainton
JA, Pertwee RG (1997) Evidence for the presence of CB2-like cannabinoid receptors on
peripheral nerve terminals. Eur J Pharmacol 339:53–61
Guhring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, Brune K (2002) A role for
endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol
454:153–163
Gutierrez T, Nackley AG, Neely MH, Freeman KG, Edwards GL, Hohmann AG (2003) Ef-
fects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid
antinocicepetion in models of acute and tonic nociception. Brain Res 987:176–185